These results suggest that DFMO disrupts PARylation in response to oxidative DNA damage, contributing to a reduced ability to repair DNA damage and an increased sensitivity to PARP inhibition in HR-competent ovarian cancer cells. Here, PARP1 is linked to ovarian cancer.